An unexplored but promising therapy is the clinical use of prolactin since administration with prolactin or prolactin-releasing peptide evidently improves steatosis in mice obesity models (137), and ablation of prolactin receptor increases hepatic triglyceride accumulation (193). This evidence concerns the gene PRLH and obesity due to melanocortin 4 receptor deficiency.